Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis
| Autor: | John P. Trafeli, Julia M. Kwan, Amy M. Reese |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.drug_class Efalizumab Dermatology Antibodies Monoclonal Humanized Monoclonal antibody medicine.disease_cause Autoimmune thrombocytopenia Autoimmunity Blood cell Psoriasis Immunopathology Humans Medicine business.industry Antibodies Monoclonal Middle Aged medicine.disease medicine.anatomical_structure Cell Migration Inhibition Immunology Anemia Hemolytic Autoimmune Autoimmune hemolytic anemia business medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology. 58:1053-1055 |
| ISSN: | 0190-9622 |
| DOI: | 10.1016/j.jaad.2008.01.021 |
| Popis: | Efalizumab, a humanized anti-CD11a monoclonal antibody, has been shown to treat plaque psoriasis. A known association between this drug and autoimmune thrombocytopenia has already been established. More recently publicized, however, is efalizumab's ability to affect another cell line--that of the erythrocyte--and cause an autoimmune hemolytic anemia that typically occurs 4 to 6 months after initiating therapy. In this article, we report the case of a patient who developed autoimmune hemolytic anemia after 8 months of successful treatment with efalizumab. His delayed presentation suggests that monitoring of blood cell counts longer than 6 months may be warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect